Jessica Donington to Neoadjuvant Therapy
This is a "connection" page, showing publications Jessica Donington has written about Neoadjuvant Therapy.
Connection Strength
0.888
-
Oncologic end points and implication of trial design in the era of immunotherapy for resectable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2023 06; 165(6):1949-1953.
Score: 0.185
-
Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer: Exciting New Horizon in Early-Stage Lung Cancer Care. Ann Surg Oncol. 2022 09; 29(9):5344-5346.
Score: 0.179
-
Surgical Issues for Operable Early-Stage Non-Small-Cell Lung Cancer. J Clin Oncol. 2022 02 20; 40(6):530-538.
Score: 0.174
-
Commentary: Why does neoadjuvant therapy suddenly make sense for early stage non-small cell lung cancer? J Thorac Cardiovasc Surg. 2020 11; 160(5):1383-1384.
Score: 0.155
-
Management of the Apical Tumor: May 4, 2013, Minneapolis, MN. Semin Thorac Cardiovasc Surg. 2013; 25(3):256-71.
Score: 0.098
-
Tumor response to induction chemoradiation: influence on survival after esophagectomy. Eur J Cardiothorac Surg. 2003 Oct; 24(4):631-6; discussion 636-7.
Score: 0.049
-
Treatment Decisions for Resectable Non-Small-Cell Lung Cancer: Balancing Less With More? Am Soc Clin Oncol Educ Book. 2023 May; 43:e389950.
Score: 0.048